In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2

P. Gentile, D. Byer, Louis Pelus

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The effects of in vivo administration of prostaglandin E2 (PGE2) on several hematologic parameters were investigated in intact mice under both steady-state conditions and in mice hematopoietically rebounding following a sublethal injection of cyclophosphamide. Intravenous injection of native PGE2, or 16,16 dimethyl-PGE2, an enzymatically stable analog of PGE2, resulted in the significant suppression of nucleated bone marrow and splenic cellularity, total resident nucleated peritoneal cells, and the absolute number of detectable granulocyte-macrophage progenitor cells (CFU-GM) per femur or spleen when administered for 3 or 7 consecutive days. The in vivo effects of 16,16 dimethyl-PGE2 were more pronounced on the cyclophosphamide-treated mice. Dose titration analysis of the effects of 16,16 dimethyl-PGE2 revealed significant suppression of hematologic parameters over a concentration range of 10 μg-10-5 μg/mouse/day (10-5 M-10-11 M). The reduction in total nucleated marrow, splenic, and peritoneal cellularity observed following PGE2 administration resulted from a selective effect on nonspecific esterase-positive cells. In situ morphological analysis of the progeny of CFU-GM proliferating in cultures established from mice treated with PGE2 in vivo indicated that the reduction in absolute CFU-GM observed resulted from a preferential effect on those colony-forming cells restricted to monocyte-macrophage differentiation. Prostaglandin F(2α) was without stimulatory or inhibitory effects in vivo on the hematopoietic parameters investigated.

Original languageEnglish (US)
Pages (from-to)1100-1107
Number of pages8
JournalBlood
Volume62
Issue number5
StatePublished - 1983
Externally publishedYes

Fingerprint

Myelopoiesis
Dinoprostone
Intravenous Administration
Modulation
Granulocyte-Macrophage Progenitor Cells
Macrophages
Cyclophosphamide
Bone Marrow
Carboxylesterase
Prostaglandins F
Titration
Intravenous Injections
Femur
Monocytes
Bone
Spleen
Cell Count
Cells
Injections

ASJC Scopus subject areas

  • Hematology

Cite this

In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. / Gentile, P.; Byer, D.; Pelus, Louis.

In: Blood, Vol. 62, No. 5, 1983, p. 1100-1107.

Research output: Contribution to journalArticle

Gentile, P, Byer, D & Pelus, L 1983, 'In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2', Blood, vol. 62, no. 5, pp. 1100-1107.
Gentile, P. ; Byer, D. ; Pelus, Louis. / In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. In: Blood. 1983 ; Vol. 62, No. 5. pp. 1100-1107.
@article{3e648ec0244b4c19af9d9505c0fedd34,
title = "In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2",
abstract = "The effects of in vivo administration of prostaglandin E2 (PGE2) on several hematologic parameters were investigated in intact mice under both steady-state conditions and in mice hematopoietically rebounding following a sublethal injection of cyclophosphamide. Intravenous injection of native PGE2, or 16,16 dimethyl-PGE2, an enzymatically stable analog of PGE2, resulted in the significant suppression of nucleated bone marrow and splenic cellularity, total resident nucleated peritoneal cells, and the absolute number of detectable granulocyte-macrophage progenitor cells (CFU-GM) per femur or spleen when administered for 3 or 7 consecutive days. The in vivo effects of 16,16 dimethyl-PGE2 were more pronounced on the cyclophosphamide-treated mice. Dose titration analysis of the effects of 16,16 dimethyl-PGE2 revealed significant suppression of hematologic parameters over a concentration range of 10 μg-10-5 μg/mouse/day (10-5 M-10-11 M). The reduction in total nucleated marrow, splenic, and peritoneal cellularity observed following PGE2 administration resulted from a selective effect on nonspecific esterase-positive cells. In situ morphological analysis of the progeny of CFU-GM proliferating in cultures established from mice treated with PGE2 in vivo indicated that the reduction in absolute CFU-GM observed resulted from a preferential effect on those colony-forming cells restricted to monocyte-macrophage differentiation. Prostaglandin F(2α) was without stimulatory or inhibitory effects in vivo on the hematopoietic parameters investigated.",
author = "P. Gentile and D. Byer and Louis Pelus",
year = "1983",
language = "English (US)",
volume = "62",
pages = "1100--1107",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2

AU - Gentile, P.

AU - Byer, D.

AU - Pelus, Louis

PY - 1983

Y1 - 1983

N2 - The effects of in vivo administration of prostaglandin E2 (PGE2) on several hematologic parameters were investigated in intact mice under both steady-state conditions and in mice hematopoietically rebounding following a sublethal injection of cyclophosphamide. Intravenous injection of native PGE2, or 16,16 dimethyl-PGE2, an enzymatically stable analog of PGE2, resulted in the significant suppression of nucleated bone marrow and splenic cellularity, total resident nucleated peritoneal cells, and the absolute number of detectable granulocyte-macrophage progenitor cells (CFU-GM) per femur or spleen when administered for 3 or 7 consecutive days. The in vivo effects of 16,16 dimethyl-PGE2 were more pronounced on the cyclophosphamide-treated mice. Dose titration analysis of the effects of 16,16 dimethyl-PGE2 revealed significant suppression of hematologic parameters over a concentration range of 10 μg-10-5 μg/mouse/day (10-5 M-10-11 M). The reduction in total nucleated marrow, splenic, and peritoneal cellularity observed following PGE2 administration resulted from a selective effect on nonspecific esterase-positive cells. In situ morphological analysis of the progeny of CFU-GM proliferating in cultures established from mice treated with PGE2 in vivo indicated that the reduction in absolute CFU-GM observed resulted from a preferential effect on those colony-forming cells restricted to monocyte-macrophage differentiation. Prostaglandin F(2α) was without stimulatory or inhibitory effects in vivo on the hematopoietic parameters investigated.

AB - The effects of in vivo administration of prostaglandin E2 (PGE2) on several hematologic parameters were investigated in intact mice under both steady-state conditions and in mice hematopoietically rebounding following a sublethal injection of cyclophosphamide. Intravenous injection of native PGE2, or 16,16 dimethyl-PGE2, an enzymatically stable analog of PGE2, resulted in the significant suppression of nucleated bone marrow and splenic cellularity, total resident nucleated peritoneal cells, and the absolute number of detectable granulocyte-macrophage progenitor cells (CFU-GM) per femur or spleen when administered for 3 or 7 consecutive days. The in vivo effects of 16,16 dimethyl-PGE2 were more pronounced on the cyclophosphamide-treated mice. Dose titration analysis of the effects of 16,16 dimethyl-PGE2 revealed significant suppression of hematologic parameters over a concentration range of 10 μg-10-5 μg/mouse/day (10-5 M-10-11 M). The reduction in total nucleated marrow, splenic, and peritoneal cellularity observed following PGE2 administration resulted from a selective effect on nonspecific esterase-positive cells. In situ morphological analysis of the progeny of CFU-GM proliferating in cultures established from mice treated with PGE2 in vivo indicated that the reduction in absolute CFU-GM observed resulted from a preferential effect on those colony-forming cells restricted to monocyte-macrophage differentiation. Prostaglandin F(2α) was without stimulatory or inhibitory effects in vivo on the hematopoietic parameters investigated.

UR - http://www.scopus.com/inward/record.url?scp=0021037662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021037662&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 1100

EP - 1107

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -